JP2005523920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523920A5 JP2005523920A5 JP2003587769A JP2003587769A JP2005523920A5 JP 2005523920 A5 JP2005523920 A5 JP 2005523920A5 JP 2003587769 A JP2003587769 A JP 2003587769A JP 2003587769 A JP2003587769 A JP 2003587769A JP 2005523920 A5 JP2005523920 A5 JP 2005523920A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- hydroxy
- phenyl
- amino
- hydroxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- JNZKLWFRYANLPN-SANMLTNESA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]benzamide Chemical compound NC(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 JNZKLWFRYANLPN-SANMLTNESA-N 0.000 claims 2
- -1 4- {2-[(2,6-dichlorobenzyl) oxy] ethoxy} phenyl Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- HJOUJGAVSAYPCU-YTTGMZPUSA-N 1-[3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]phenyl]-3-phenylurea Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(NC(=O)NC=4C=CC=CC=4)C=CC=3)=CC=2)=C1 HJOUJGAVSAYPCU-YTTGMZPUSA-N 0.000 claims 1
- LQJULLFJFVMTFW-SANMLTNESA-N 1-hydroxy-2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-[2-[[3-(sulfamoylamino)phenyl]methoxy]ethoxy]phenyl]ethylamino]ethyl]benzene Chemical compound NS(=O)(=O)NC1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 LQJULLFJFVMTFW-SANMLTNESA-N 0.000 claims 1
- WKSMVEKKPNZWHI-MHZLTWQESA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-(4-phenylbutoxy)phenyl]ethylamino]ethyl]phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCCCC=3C=CC=CC=3)=CC=2)=C1 WKSMVEKKPNZWHI-MHZLTWQESA-N 0.000 claims 1
- WQEQIHWZMZZIGF-MHZLTWQESA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-[2-[(3-methylphenyl)methoxy]ethoxy]phenyl]ethylamino]ethyl]phenol Chemical compound CC1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 WQEQIHWZMZZIGF-MHZLTWQESA-N 0.000 claims 1
- BTUNEKRXBIXQAL-VFIQEOMOSA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-[2-[(3-propan-2-ylsulfinylphenyl)methoxy]ethoxy]phenyl]ethylamino]ethyl]phenol Chemical compound CC(C)S(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 BTUNEKRXBIXQAL-VFIQEOMOSA-N 0.000 claims 1
- PQVGTLJBZRQASF-LJAQVGFWSA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-[2-[(3-propan-2-ylsulfonylphenyl)methoxy]ethoxy]phenyl]ethylamino]ethyl]phenol Chemical compound CC(C)S(=O)(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 PQVGTLJBZRQASF-LJAQVGFWSA-N 0.000 claims 1
- KJBAUVWGFNMHCY-LJAQVGFWSA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-[2-[(4-propan-2-yloxyphenyl)methoxy]ethoxy]phenyl]ethylamino]ethyl]phenol Chemical compound C1=CC(OC(C)C)=CC=C1COCCOC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C(CO)=C1 KJBAUVWGFNMHCY-LJAQVGFWSA-N 0.000 claims 1
- JEWPRFHZTUZKJG-HRFSGMKKSA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[[(2r)-1-[4-(2-phenylmethoxyethoxy)phenyl]propan-2-yl]amino]ethyl]phenol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(CO)C(O)=CC=1)C(C=C1)=CC=C1OCCOCC1=CC=CC=C1 JEWPRFHZTUZKJG-HRFSGMKKSA-N 0.000 claims 1
- JEWPRFHZTUZKJG-DCFHFQCYSA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[[(2s)-1-[4-(2-phenylmethoxyethoxy)phenyl]propan-2-yl]amino]ethyl]phenol Chemical compound C([C@H](C)NC[C@H](O)C=1C=C(CO)C(O)=CC=1)C(C=C1)=CC=C1OCCOCC1=CC=CC=C1 JEWPRFHZTUZKJG-DCFHFQCYSA-N 0.000 claims 1
- HDROXKWFISBWIP-PMERELPUSA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]-n-(2-methylpropyl)benzamide Chemical compound CC(C)CNC(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 HDROXKWFISBWIP-PMERELPUSA-N 0.000 claims 1
- JOYRSIZIYWVNQH-HKBQPEDESA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]-n-(3-methylbutyl)benzamide Chemical compound CC(C)CCNC(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 JOYRSIZIYWVNQH-HKBQPEDESA-N 0.000 claims 1
- KVRZZNRPZMNLJX-MHZLTWQESA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 KVRZZNRPZMNLJX-MHZLTWQESA-N 0.000 claims 1
- QVNONZSPCSRYNJ-HKBQPEDESA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]-n-pentylbenzamide Chemical compound CCCCCNC(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 QVNONZSPCSRYNJ-HKBQPEDESA-N 0.000 claims 1
- SNUIYHXSKVXXKI-LJAQVGFWSA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 SNUIYHXSKVXXKI-LJAQVGFWSA-N 0.000 claims 1
- DTQOMXBSNPSSKH-LJAQVGFWSA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]-n-propan-2-ylbenzenesulfonamide Chemical compound CC(C)NS(=O)(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 DTQOMXBSNPSSKH-LJAQVGFWSA-N 0.000 claims 1
- APAVDTGQHPYAKS-SANMLTNESA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 APAVDTGQHPYAKS-SANMLTNESA-N 0.000 claims 1
- XQHVYGUNIOVSJJ-SANMLTNESA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]benzoic acid Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(C=CC=3)C(O)=O)=CC=2)=C1 XQHVYGUNIOVSJJ-SANMLTNESA-N 0.000 claims 1
- XLRMMQYMRGOQIA-MHZLTWQESA-N 3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]benzonitrile Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(C=CC=3)C#N)=CC=2)=C1 XLRMMQYMRGOQIA-MHZLTWQESA-N 0.000 claims 1
- JILSRQIUVCFOLR-YTTGMZPUSA-N 3-[3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]phenyl]benzoic acid Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(C=CC=3)C=3C=C(C=CC=3)C(O)=O)=CC=2)=C1 JILSRQIUVCFOLR-YTTGMZPUSA-N 0.000 claims 1
- BYKUWDIYOOQTQF-MHZLTWQESA-N 3-[4-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]butyl]benzamide Chemical compound NC(=O)C1=CC=CC(CCCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 BYKUWDIYOOQTQF-MHZLTWQESA-N 0.000 claims 1
- ULOCBHKWCQDACV-MHZLTWQESA-N 3-[4-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]butyl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CCCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 ULOCBHKWCQDACV-MHZLTWQESA-N 0.000 claims 1
- LJYJKCVTJDLWSL-MHZLTWQESA-N 3-[4-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]butyl]benzoic acid Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCCCC=3C=C(C=CC=3)C(O)=O)=CC=2)=C1 LJYJKCVTJDLWSL-MHZLTWQESA-N 0.000 claims 1
- KDQVAHWKNIVUOI-NDEPHWFRSA-N 3-[4-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]butyl]benzonitrile Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCCCC=3C=C(C=CC=3)C#N)=CC=2)=C1 KDQVAHWKNIVUOI-NDEPHWFRSA-N 0.000 claims 1
- QUQTWERJGAAIRK-SANMLTNESA-N 4-[(1r)-1-hydroxy-2-[2-[4-[2-[(3-hydroxyphenyl)methoxy]ethoxy]phenyl]ethylamino]ethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(O)C=CC=3)=CC=2)=C1 QUQTWERJGAAIRK-SANMLTNESA-N 0.000 claims 1
- JPAHMDHRDXOPTQ-SANMLTNESA-N 4-[(1r)-1-hydroxy-2-[2-[4-[2-[(3-iodophenyl)methoxy]ethoxy]phenyl]ethylamino]ethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(I)C=CC=3)=CC=2)=C1 JPAHMDHRDXOPTQ-SANMLTNESA-N 0.000 claims 1
- RDQRXWXUIWLWLT-SANMLTNESA-N 4-[(1r)-1-hydroxy-2-[2-[4-[2-[(4-hydroxyphenyl)methoxy]ethoxy]phenyl]ethylamino]ethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=CC(O)=CC=3)=CC=2)=C1 RDQRXWXUIWLWLT-SANMLTNESA-N 0.000 claims 1
- FTPHBJZULJSOKG-MHZLTWQESA-N 4-[(1r)-1-hydroxy-2-[2-[4-[4-(3-hydroxyphenyl)butoxy]phenyl]ethylamino]ethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCCCC=3C=C(O)C=CC=3)=CC=2)=C1 FTPHBJZULJSOKG-MHZLTWQESA-N 0.000 claims 1
- XYSWHNDONUHOMQ-SANMLTNESA-N 4-[(1r)-2-[2-[4-[2-[(3-chlorophenyl)methoxy]ethoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(Cl)C=CC=3)=CC=2)=C1 XYSWHNDONUHOMQ-SANMLTNESA-N 0.000 claims 1
- TUSVOIRNHYXJPF-HKBQPEDESA-N 4-[(1r)-2-[2-[4-[2-[(3-cyclopentylsulfonylphenyl)methoxy]ethoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(C=CC=3)S(=O)(=O)C3CCCC3)=CC=2)=C1 TUSVOIRNHYXJPF-HKBQPEDESA-N 0.000 claims 1
- FOUQOVSRJGYOKB-SANMLTNESA-N 4-[(1r)-2-[2-[4-[2-[(3-fluorophenyl)methoxy]ethoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(F)C=CC=3)=CC=2)=C1 FOUQOVSRJGYOKB-SANMLTNESA-N 0.000 claims 1
- LJLPGDSIHCPFBN-SANMLTNESA-N 4-[(1r)-2-[2-[4-[2-[(4-fluorophenyl)methoxy]ethoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=CC(F)=CC=3)=CC=2)=C1 LJLPGDSIHCPFBN-SANMLTNESA-N 0.000 claims 1
- IFAZUFLEOBMCSI-MHZLTWQESA-N 4-[(1r)-2-[2-[4-[4-(2,6-dichlorophenyl)butoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCCCC=3C(=CC=CC=3Cl)Cl)=CC=2)=C1 IFAZUFLEOBMCSI-MHZLTWQESA-N 0.000 claims 1
- BYLDLECQHHPQIR-DKHGMYDOSA-N 4-[(1r)-2-[2-[4-[4-(3-cyclopentylsulfinylphenyl)butoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCCCC=3C=C(C=CC=3)S(=O)C3CCCC3)=CC=2)=C1 BYLDLECQHHPQIR-DKHGMYDOSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 1
- JTRQAWCAZAEUDH-SANMLTNESA-N O[C@@H](CNCCC1=CC=C(OCCOCC=2C=C(C=CC2)NC(OC(N)=N)=N)C=C1)C1=CC(=C(C=C1)O)CO Chemical compound O[C@@H](CNCCC1=CC=C(OCCOCC=2C=C(C=CC2)NC(OC(N)=N)=N)C=C1)C1=CC(=C(C=C1)O)CO JTRQAWCAZAEUDH-SANMLTNESA-N 0.000 claims 1
- IVGLUKPDEFGQDS-SANMLTNESA-N [3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]phenyl]urea Chemical compound NC(=O)NC1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 IVGLUKPDEFGQDS-SANMLTNESA-N 0.000 claims 1
- VNAAEYYDEKQYFS-MHZLTWQESA-N [3-[4-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]butyl]phenyl]urea Chemical compound NC(=O)NC1=CC=CC(CCCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 VNAAEYYDEKQYFS-MHZLTWQESA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IRQGPHWUKAEEQX-NDEPHWFRSA-N n-[3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 IRQGPHWUKAEEQX-NDEPHWFRSA-N 0.000 claims 1
- MDEIDIPDMVUGHW-LJAQVGFWSA-N n-[3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]phenyl]furan-2-carboxamide Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(NC(=O)C=4OC=CC=4)C=CC=3)=CC=2)=C1 MDEIDIPDMVUGHW-LJAQVGFWSA-N 0.000 claims 1
- IGKADIGWLZOWSN-MHZLTWQESA-N n-[3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(COCCOC=2C=CC(CCNC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=2)=C1 IGKADIGWLZOWSN-MHZLTWQESA-N 0.000 claims 1
- UMMRBFFDNGBJHU-HKBQPEDESA-N n-[3-[2-[4-[2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]ethoxymethyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OCCOCC=3C=C(NC(=O)C=4C=NC=CC=4)C=CC=3)=CC=2)=C1 UMMRBFFDNGBJHU-HKBQPEDESA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0209482A GB0209482D0 (en) | 2002-04-25 | 2002-04-25 | Medicinal compounds |
| GB0225027A GB0225027D0 (en) | 2002-10-28 | 2002-10-28 | Medicinal compounds |
| PCT/EP2003/004367 WO2003091204A1 (en) | 2002-04-25 | 2003-04-24 | Phenethanolamine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523920A JP2005523920A (ja) | 2005-08-11 |
| JP2005523920A5 true JP2005523920A5 (enExample) | 2006-01-26 |
Family
ID=29272000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587769A Pending JP2005523920A (ja) | 2002-04-25 | 2003-04-24 | フェネタノールアミン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7271197B2 (enExample) |
| EP (1) | EP1497261B1 (enExample) |
| JP (1) | JP2005523920A (enExample) |
| AT (1) | ATE381535T1 (enExample) |
| AU (1) | AU2003222841A1 (enExample) |
| DE (1) | DE60318193T2 (enExample) |
| ES (1) | ES2298511T3 (enExample) |
| WO (1) | WO2003091204A1 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1487417A4 (en) | 2001-09-17 | 2010-03-17 | Glaxo Group Ltd | DRY POWDER DRUG FORMULATIONS |
| DE602004024383D1 (de) | 2003-05-08 | 2010-01-14 | Theravance Inc | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists |
| TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| GB0324654D0 (en) * | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0403864D0 (en) * | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| EA200601510A1 (ru) * | 2004-03-17 | 2007-04-27 | Пфайзер Инк. | Производные фенилэтаноламина в качестве бета-2-агонистов |
| EP1577291A1 (en) * | 2004-03-17 | 2005-09-21 | Pfizer Limited | Phenylethanolamine derivatives as beta-2 agonists |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| EP1786762A2 (en) | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0425057D0 (en) * | 2004-11-12 | 2004-12-15 | Pfizer Ltd | L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| JP5281291B2 (ja) | 2005-01-10 | 2013-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| EA200801997A1 (ru) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | Новые соединения |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| CL2007001829A1 (es) | 2006-06-23 | 2008-01-25 | Smithkline Beecham Corp | P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc. |
| NZ574533A (en) | 2006-08-01 | 2011-05-27 | Glaxo Group Ltd | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| ES2302447B1 (es) * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| AU2007342223B2 (en) | 2007-01-10 | 2011-02-24 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| CA2677485A1 (en) | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| EP2332933A1 (en) | 2007-05-07 | 2011-06-15 | Novartis AG | Epithelial sodium channel (ENaC) inhibitors |
| ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
| BRPI0820669A2 (pt) | 2007-12-10 | 2020-08-04 | Novartis Ag | compostos orgânicos |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
| JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ，エルエルシー． | ５−リポキシゲナーゼ活性化タンパク質阻害剤 |
| EP2280946B1 (en) | 2008-06-05 | 2016-02-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| PL2379507T3 (pl) | 2008-12-30 | 2014-03-31 | Pulmagen Therapeutics Inflammation Ltd | Związki sulfonamidu do leczenia zaburzeń układu oddechowego |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Ｉｔｋ阻害剤として使用されるピリミジン誘導体 |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| AU2010226604A1 (en) | 2009-03-19 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing |
| EP2411517A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
| RS53830B1 (sr) | 2009-04-30 | 2015-06-30 | Glaxo Group Limited | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| US20120272951A1 (en) | 2009-12-16 | 2012-11-01 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
| HRP20151017T1 (hr) | 2010-09-08 | 2015-10-23 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
| WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| BR112013021638A2 (pt) | 2011-02-25 | 2016-08-02 | Irm Llc | "compostos inibidores de trk, seu uso e composições que os compreendem" |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | Ｎ−置換ヘテロシクリルカルボキサミド類 |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP3057588A1 (en) | 2013-10-17 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| KR20160062179A (ko) | 2013-10-17 | 2016-06-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제 |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| AU2014391610B2 (en) | 2014-04-24 | 2018-01-25 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| US20200383960A1 (en) | 2019-06-10 | 2020-12-10 | Novartis Ag | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis |
| KR20220052934A (ko) | 2019-08-28 | 2022-04-28 | 노파르티스 아게 | 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도 |
| CN116283512B (zh) * | 2023-02-24 | 2025-04-25 | 博诺康源(北京)药业科技有限公司 | 一种合成维兰特罗及其盐的方法 |
| CN121986087A (zh) * | 2023-10-13 | 2026-05-05 | 国立研究开发法人国立精神·神经医疗研究中心 | 神经保护剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
| DK172541B1 (da) * | 1982-10-08 | 1998-12-07 | Glaxo Group Ltd | Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet |
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| DE3513885A1 (de) | 1984-04-17 | 1985-10-17 | Glaxo Group Ltd., London | Phenethanolaminverbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| FI944549L (fi) * | 1992-04-02 | 1994-11-30 | Smithkline Beecham Corp | Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet |
| WO1998024753A1 (en) | 1996-12-02 | 1998-06-11 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same |
| JPH10152460A (ja) | 1996-11-21 | 1998-06-09 | Kissei Pharmaceut Co Ltd | ２−アミノ−１−（４−ヒドロキシ−２−メチルフェニル）プロパノール誘導体 |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| SI1070056T1 (en) | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
| PL200923B1 (pl) | 1999-08-21 | 2009-02-27 | Nycomed Gmbh | Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu |
-
2003
- 2003-04-24 AT AT03718792T patent/ATE381535T1/de not_active IP Right Cessation
- 2003-04-24 AU AU2003222841A patent/AU2003222841A1/en not_active Abandoned
- 2003-04-24 ES ES03718792T patent/ES2298511T3/es not_active Expired - Lifetime
- 2003-04-24 JP JP2003587769A patent/JP2005523920A/ja active Pending
- 2003-04-24 DE DE60318193T patent/DE60318193T2/de not_active Expired - Fee Related
- 2003-04-24 EP EP03718792A patent/EP1497261B1/en not_active Expired - Lifetime
- 2003-04-24 US US10/512,232 patent/US7271197B2/en not_active Expired - Fee Related
- 2003-04-24 WO PCT/EP2003/004367 patent/WO2003091204A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509852A5 (enExample) | ||
| RU2312854C2 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| JP2007509103A5 (enExample) | ||
| DE60318193T2 (de) | Phenethanolaminderivate | |
| ES2578404T3 (es) | Moduladores de la indolamina 2,3-dioxigenasa, y métodos de uso de los mismos | |
| RU2238933C2 (ru) | Аминобензофеноны как ингибиторы ил-1 бэта и tnf-альфа | |
| JP2005522438A5 (enExample) | ||
| RU2004112780A (ru) | Производные и промежуточные соединения n-адамантилметила в качестве фармацевтических композиций и способы их получения | |
| RU2002132385A (ru) | Новые соединения | |
| CA2448356A1 (en) | N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands | |
| JP2004524308A5 (enExample) | ||
| JP2007505164A5 (enExample) | ||
| JP2012515166A5 (enExample) | ||
| RU2005111975A (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| TW200424174A (en) | New TP diamide | |
| JP2011526594A5 (enExample) | ||
| RU2006113700A (ru) | Аминозамещенный этиламито-агонисты бэта2-адренергических рецепторов | |
| RU2006102127A (ru) | Производные хинолина и их применение в терапии | |
| CZ20023479A3 (cs) | Cyklohexylaminový derivát, jako subtyp selektivních antagonistů NMDA receptoru | |
| RU2010139571A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола в качестве агонистов b2-адренергического рецептора | |
| JP2004524345A5 (enExample) | ||
| JP2011506463A5 (enExample) | ||
| EP0799191A1 (en) | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | |
| JP2009514899A5 (enExample) | ||
| US20110092468A1 (en) | Pharmaceutical Calcimimetics |